HuGE Literature Finder
|
Records 1-3
RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
International journal of cancer 2016 Mar . Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Konishi Tsuyoshi, Akiyoshi Takashi, Fujimoto Yoshiya, Nagayama Satoshi, Fukunaga Yosuke, Ueno Masashi, Mise Yoshihiro, Ishizawa Takeaki, Inoue Yosuke, Takahashi Yu, Saiura Akio, Uehara Hirohumi, Mun Mingyon, Okumura Sakae, Mizunuma Nobuyuki, Miki Yoshio, Yamaguchi Toshiha |
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Jan 26 (1): 13-21. Sorich M J, Wiese M D, Rowland A, Kichenadasse G, McKinnon R A, Karapetis C |
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64. Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M |
- Page last reviewed:Jul 30, 2019
- Page last updated:Dec 5, 2019
- Content source: